KB-0118
KB-0118 (BBC0115) is an inhibitor targeting the BET bromodomain. It selectively binds to BRD2 and BRD4, with dissociation constants (Kd) of 36.7 μM for BRD2 BD1 and 47.4 μM for BRD4 BD1, while not binding to BRD3. KB-0118 suppresses the secretion of pro-inflammatory cytokines such as TNF, IL-1β, and IL-23a, and selectively inhibits Th17 cell differentiation. The compound regulates Th17-driven inflammation through the epigenetic suppression of BRD4, as evidenced by the downregulation of STAT3 and BRD4 target genes. Additionally, KB-0118 exhibits immunomodulatory effects in inflammatory bowel disease (IBD) models.
Product Specifications
CAS Number
2648377-08-4
Field of Research
Epigenetics & Chromatin, Immunology & Inflammation, Signal Transduction, Stem Cell & Developmental Biology
Smiles
O=C1C (O) =C (OC=2C=C (O) C=C (O) C12) C=3C=CC=4C=CNC4C3
Molecular Formula
C17H11NO5
Molecular Weight
309.27
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Interleukin 2, Recombinant, Human (Interleukin-2, IL-2, IL2, Aldesleukin, Lymphokine, T-cell Growth Factor, TCGF)
Interleukin 2, Recombinant, Human (Interleukin-2, IL-2, IL2, Aldesleukin, Lymphokine, T-cell Growth Factor, TCGF)
Interleukin 2, Recombinant, Human (Interleukin-2, IL-2, IL2, Aldesleukin, Lymphokine, T-cell Growth Factor, TCGF)
4-Bromo-1-cyclopentyl-1H-pyrazole-5-carboxylic acid
4-Bromo-1-cyclopentyl-1H-pyrazole-5-carboxylic acid
